Melatonin: What the Research Has Measured

This content is educational. It describes what research has measured about melatonin. It is not medical advice or dose recommendation. Melatonin is a hormone with effects on multiple body systems. Consult a healthcare professional before considering supplementation, particularly for children, during pregnancy, or if you take prescription medication.

Why this matters

Melatonin is among the most-used over-the-counter sleep supplements in the world. In the US, melatonin sales have grown more than 150% in the past decade. It's marketed widely, available in supermarkets, and often the first thing consumers try for sleep difficulty.

The research behind melatonin is genuinely interesting. It's also more nuanced than the marketing suggests — the doses used in successful trials are dramatically lower than what most consumer products contain, the indication matters enormously, and several safety questions warrant more attention than they typically receive.

This page describes what the research has actually measured.

What melatonin is

Melatonin is a hormone produced by the pineal gland (a small structure in the brain) primarily in response to darkness. Production peaks at night, dropping sharply with morning light. The body's natural melatonin signalling is the primary mechanism by which the circadian rhythm tells the body it's time to sleep.

Supplemental melatonin is a synthetic version of the same molecule. When taken externally, it can influence circadian timing and, at higher doses, can act as a mild sedative.

The distinction matters because supplemental melatonin has two quite different uses in the research literature:

Circadian use (low doses, specific timing). Small amounts of melatonin (0.3-1 mg) taken at specific times can shift the circadian rhythm — useful for jet lag, shift work, and certain circadian disorders.

Sedative use (higher doses, near bedtime). Larger doses (3-10 mg) at bedtime produce a mild sedative effect — easier sleep onset for some people.

Most consumer melatonin products are dosed for the sedative use — and dosed substantially higher than the doses studied even for that purpose.

What the dose research describes

This is where the consumer market diverges most from the research.

The studied doses for sleep effects are smaller than most consumers realise:

• Jet lag and circadian shifting — trials typically use 0.3-1 mg taken several hours before the target sleep time, several days in a row
• Sleep onset latency (time to fall asleep) — meta-analyses report measurable effects at 0.3-5 mg [Auld et al. 2017]
• Sleep maintenance (staying asleep) — extended-release formulations at 2 mg have been most studied for older adults [Wade et al. 2011]
• Children with sleep disorders (under specialist care) — typically 0.5-3 mg

Most consumer products contain 5, 10, or even 20 mg per serving — dramatically higher than the studied effective dose for any indication.

A 2017 review in Sleep Medicine Reviews noted that increasing the dose above approximately 0.3-3 mg does not increase the sleep-onset effect, but does increase next-morning grogginess and the risk of side effects [Auld et al. 2017]. The over-dosing in consumer products doesn't make them more effective; it just makes them more likely to produce unwanted effects.

A 2017 analysis of melatonin products on the US market found that actual melatonin content ranged from -83% to +478% of label claim, with one in four products containing significant contamination from other compounds [Erland & Saxena 2017]. Product quality is a real issue in the unregulated US market for melatonin.

What controlled trials have measured

Several patterns emerge from the trial literature:

Sleep onset latency

Meta-analyses have reported that melatonin reduces sleep onset latency by approximately 7-12 minutes on average compared with placebo. The effect is real but modest. People with longer baseline sleep onset latency see larger improvements than those who already fall asleep quickly [Brzezinski et al. 2005; Ferracioli-Oda et al. 2013].

Total sleep time

Modest increase — typically 8-25 minutes additional total sleep across trial averages. Effect size is small compared with the highest-leverage sleep interventions (see our Sleep Research Brief).

Sleep quality

Subjective sleep quality improvements have been measured across multiple trials. Objective sleep architecture changes (deep sleep, REM proportion) are typically small.

Jet lag

Among the strongest indications for melatonin. A 2002 Cochrane review concluded that melatonin is "remarkably effective" for preventing or reducing jet lag, particularly for travel across 5+ time zones [Herxheimer & Petrie 2002].

Shift work

Modest evidence for sleep timing in shift workers, with mixed real-world adherence and effect persistence.

Delayed sleep phase syndrome (DSPS)

Clinical evidence supports low-dose melatonin (0.5 mg) taken at specific times for adolescents and adults with diagnosed delayed sleep phase. This is a clinical application typically supervised by a sleep specialist.

Older adults with insomnia

Extended-release melatonin (Circadin in EU markets) has prescription approval for primary insomnia in adults aged 55+ in Europe. The evidence base is reasonable for this specific indication [Wade et al. 2011].

Children with neurodevelopmental conditions

Sleep disturbance is common in children with autism, ADHD, and certain neurodevelopmental conditions. Melatonin is widely used in this context under pediatric specialist guidance, with reasonable evidence base. Self-administration without specialist guidance is a different matter.

Safety considerations

The marketing around melatonin often implies it's universally safe because it's a natural hormone. The research suggests several specific concerns.

Drug interactions

Melatonin interacts with multiple medication classes:

• Anticoagulants (warfarin, others) — may increase bleeding risk
• Immunosuppressants — may affect immune function
• Diabetes medications — may affect glucose tolerance
• Sedatives and other CNS depressants — additive sedation
• Hormonal contraceptives — may increase melatonin levels
• Blood pressure medications — variable effects

If you take prescription medication, melatonin warrants discussion with your pharmacist or prescribing clinician before use.

Hormonal effects

Melatonin is a hormone. Long-term high-dose use has effects on:

• Reproductive hormone production in animal studies (human relevance is contested)
• Glucose tolerance in some studies
• Cardiovascular markers in some studies

Long-term human safety data at high consumer doses (5-10 mg nightly for years) is limited. The published trials typically run weeks to months, not years.

Children

The use of melatonin in healthy children without specialist guidance is concerning to many sleep researchers. The hormonal effects of long-term supplemental melatonin during development are not well characterised. The American Academy of Pediatrics has expressed concern about unsupervised pediatric melatonin use [Esposito et al. 2019; AAP advisory 2022].

Pediatric melatonin use should be under medical supervision.

Pregnancy

Melatonin is generally not recommended during pregnancy and breastfeeding due to insufficient safety data. Some specific clinical indications exist under obstetric supervision; general pregnancy use is not advised.

Dependence and tolerance

Melatonin doesn't produce the classical dependence patterns of prescription sleep medications. Some users report tolerance — needing higher doses for the same effect — though the research literature is mixed on this. Most reviews don't find strong evidence for tolerance development.

Discontinuation

Stopping melatonin after long-term use occasionally produces rebound sleep difficulty for a few days. This is generally mild and self-limiting.

Timing considerations

For sleep onset effects, melatonin is typically studied taken 30-60 minutes before intended sleep time. Earlier doses may not be as effective; later doses can produce next-morning grogginess.

For circadian shifting (jet lag, DSPS), the optimal timing depends on the direction of the desired shift. Several hours before the target sleep time is typical. Specific timing protocols exist for specific indications.

Comparison with other sleep interventions

When considering melatonin in the context of broader sleep research:

• The highest-effect-size sleep interventions (bedroom temperature, morning light, caffeine timing, consistent sleep timing) typically outperform melatonin for chronic sleep concerns. See our Sleep Research Brief
• Melatonin is particularly useful for circadian timing problems (jet lag, shift work, DSPS) where behavioural interventions can't address the underlying biology
• For acute occasional sleep difficulty, low-dose melatonin has modest evidence
• For chronic insomnia, CBT-I (cognitive-behavioural therapy for insomnia) has substantially stronger evidence than melatonin

The honest framing: melatonin is one tool among many for specific situations. It is not the first-line intervention for most sleep concerns, despite its consumer prominence.

What this means for consumers

If you're considering melatonin:

1. Lower doses are better. The studied effective range is 0.3-3 mg for most indications. The 5-10 mg consumer products aren't more effective and increase side-effect risk.

2. Timing matters. For sleep onset, 30-60 minutes before intended sleep. For circadian shifting, the protocol depends on the goal.

3. Product quality varies enormously. In unregulated markets, melatonin content often differs substantially from label claim. Pharmaceutical-grade or third-party-tested products are more reliable.

4. Drug interactions are real. If you take prescription medication, consult your pharmacist before use.

5. Children and pregnant/breastfeeding people: specialist consultation is warranted before any use.

6. Long-term use is less well-studied than short-term use. The published evidence at high consumer doses over years is sparse.

7. Consider whether the underlying problem is one melatonin addresses. Persistent insomnia warrants clinical evaluation rather than ongoing self-medication.

For most adults with occasional sleep difficulty, low-dose melatonin used short-term has reasonable evidence and acceptable safety. For chronic sleep concerns, the highest-leverage behavioural interventions and clinical evaluation are typically better first steps.

What Proco's editorial position is

Melatonin is a real intervention with a real evidence base for specific indications. It is also marketed substantially more aggressively than the evidence supports, dosed substantially higher than studies show effective, and used in populations (particularly children) where the evidence base is concerning.

For the Scanner specifically: when you scan a melatonin product, the app shows the dose, the form, the studied effective range for the relevant indications, and the known drug interactions. It doesn't tell you whether to take it — that decision belongs with you and (where warranted) a clinician.

Related Proco pages

• Sleep stages: what NREM and REM actually are
• Sleep deprivation research
• How sleep apnea is diagnosed
• How much sleep do you actually need

Sources

Proco provides educational, research-based information. This page describes what melatonin research has measured. It is not medical advice or dose recommendation. Melatonin is a hormone with effects on multiple body systems. If you are pregnant, breastfeeding, take prescription medication, manage a chronic condition, or are considering use for a child, talk to a qualified healthcare professional.

Schema (for implementation)

{
  "@context": "https://schema.org",
  "@type": "MedicalWebPage",
  "headline": "Melatonin: What the Research Has Measured",
  "description": "Melatonin is among the most-used sleep supplements. The studied effective dose range is 0.3-3 mg — substantially lower than most consumer products. This page describes what the research actually measures.",
  "datePublished": "2026-06-01",
  "dateModified": "2026-05-31",
  "author": {"@type": "Organization", "name": "Proco"},
  "publisher": {"@type": "Organization", "name": "Proco", "url": "https://procohq.com"},
  "medicalAudience": "Patient",
  "about": {"@type": "Thing", "name": "Melatonin research"}
}